Home / News / India News / Article / Glenmark announces 400 mg 'FabiFlu' for COVID-19 treatment

Glenmark announces 400 mg 'FabiFlu' for COVID-19 treatment

Mid Day Short Description

  • WhatsAppBookmarkBookmark
Listen to this article :
This picture has been used for representation purpose

This picture has been used for representation purpose

Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to introduce a 400 mg version of oral antiviral - FabiFlu -- for the treatment of mild to moderate Covid-19 in India.

It was the first Indian company to commercially launch an antiviral drug - Favipiravir with brand name FabiFlu - for the treatment of Covid-19 patients. The company received marketing and manufacturing approval from the Drug Controller General of India and launched the product in the Indian market on June 20.

Read Next Story
Document in Mallya case in Supreme Court missing, next hearing Aug 20›

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All